TY - JOUR
T1 - Central versus paracentral cone location and outcomes of accelerated cross-linking in keratoconus patients
AU - KEI CXL Study Group
AU - Mimouni, Michael
AU - Sorkin, Nir
AU - Trinh, Tanya
AU - Stein, Raymond
AU - Bujak, Matthew C.
AU - Chan, Clara C.
AU - Chew, Hall F.
AU - El-Defrawy, Sherif
AU - Kranemann, Christoph
AU - Rabinovitch, Theodore
AU - Rootman, David S.
AU - Slomovic, Allan R.
AU - Hatch, Wendy
AU - Singal, Neera
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
PY - 2021/12
Y1 - 2021/12
N2 - Purpose: To compare outcomes 1 year after accelerated cross-linking (CXL) between keratoconus eyes with central cones to those with paracentral cones. Methods: In this post hoc analysis of data from a prospective multicentre study, consecutive progressive keratoconus eyes treated with accelerated CXL were included. Preoperative and 1 year post CXL manifest refraction, corneal cylinder, maximal keratometry (Kmax), central corneal thickness and coma were assessed. Central and paracentral cones were defined as cones within the central 3 mm and those between 3 and 5 mm, respectively. Eyes with apical scarring and peripheral cones (>5 mm) were excluded. The primary outcome measures were changes in best spectacle-corrected visual acuity (BSCVA) and Kmax. Results: Overall, 314 eyes (n = 314) with a mean age of 27.5 ± 7.7 years were included. At baseline, the central cone group was younger (p < 0.001), had lower corneal astigmatism (p = 0.03) and coma (p = 0.02). At 1 year post CXL, after adjusting for baseline characteristics (age, BSCVA, corneal astigmatism, Kmax and coma), the central cone group showed a greater reduction in myopia (mean difference 1.27 ± 0.60D, p = 0.04) and more improvement in BSCVA (mean difference 0.08 ± 0.02 logMAR, p < 0.001) compared to the paracentral group. There was no significant difference in progression rates between the central and paracentral groups (ΔKmax > 2D, 6.7% vs. 6.5%, respectively, p = 0.83). Conclusions: This large-scale study of keratoconus eyes 1 year after accelerated CXL indicates that compared to those with paracentral cones, central cones have on average almost one additional line improvement in BCSVA and 1.27 D more reduction in myopia.
AB - Purpose: To compare outcomes 1 year after accelerated cross-linking (CXL) between keratoconus eyes with central cones to those with paracentral cones. Methods: In this post hoc analysis of data from a prospective multicentre study, consecutive progressive keratoconus eyes treated with accelerated CXL were included. Preoperative and 1 year post CXL manifest refraction, corneal cylinder, maximal keratometry (Kmax), central corneal thickness and coma were assessed. Central and paracentral cones were defined as cones within the central 3 mm and those between 3 and 5 mm, respectively. Eyes with apical scarring and peripheral cones (>5 mm) were excluded. The primary outcome measures were changes in best spectacle-corrected visual acuity (BSCVA) and Kmax. Results: Overall, 314 eyes (n = 314) with a mean age of 27.5 ± 7.7 years were included. At baseline, the central cone group was younger (p < 0.001), had lower corneal astigmatism (p = 0.03) and coma (p = 0.02). At 1 year post CXL, after adjusting for baseline characteristics (age, BSCVA, corneal astigmatism, Kmax and coma), the central cone group showed a greater reduction in myopia (mean difference 1.27 ± 0.60D, p = 0.04) and more improvement in BSCVA (mean difference 0.08 ± 0.02 logMAR, p < 0.001) compared to the paracentral group. There was no significant difference in progression rates between the central and paracentral groups (ΔKmax > 2D, 6.7% vs. 6.5%, respectively, p = 0.83). Conclusions: This large-scale study of keratoconus eyes 1 year after accelerated CXL indicates that compared to those with paracentral cones, central cones have on average almost one additional line improvement in BCSVA and 1.27 D more reduction in myopia.
UR - http://www.scopus.com/inward/record.url?scp=85100558930&partnerID=8YFLogxK
U2 - 10.1038/s41433-021-01404-5
DO - 10.1038/s41433-021-01404-5
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33514906
AN - SCOPUS:85100558930
SN - 0950-222X
VL - 35
SP - 3311
EP - 3317
JO - Eye
JF - Eye
IS - 12
ER -